Medicaid and Children's Health Insurance Program (CHIP) Generic Information Collection Activities: Proposed Collection; Comment Request, 10367-10369 [2022-03936]
Download as PDF
Federal Register / Vol. 87, No. 37 / Thursday, February 24, 2022 / Notices
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–03871 Filed 2–23–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors, Center
for Preparedness and Response, (BSC,
CPR); Meeting
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Board of Scientific Counselors,
Center for Preparedness and Response,
(BSC, CPR). This is a virtual meeting
that is open to the public, limited only
by the number of internet conference
accesses available, which is 500. Time
will be available for public comment.
Pre-registration is required by accessing
the link in the addresses section.
DATES: The meeting will be held on
March 24, 2022, from 1:00 p.m. to 3:00
p.m., EDT.
ADDRESSES: Zoom Virtual Meeting. If
you wish to attend the virtual meeting,
please pre-register by accessing the link
at: https://cdc.zoomgov.com/webinar/
register/WN_M20Tm8MUTbihUhvg0BcSg. Instructions to access the
Zoom virtual meeting will be provided
in the link following registration.
FOR FURTHER INFORMATION CONTACT:
Dometa Ouisley, Office of Science and
Public Health Practice, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop–H21–6,
Atlanta, Georgia 30329–4027,
Telephone: (404) 639–7450; Facsimile:
(678) 669–1667; Email: DOuisley@
cdc.gov.
jspears on DSK121TN23PROD with NOTICES1
SUMMARY:
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
16:46 Feb 23, 2022
Jkt 256001
Purpose: The Board is charged with
providing advice and guidance to the
Secretary, Department of Health and
Human Services (HHS), the Assistant
Secretary for Health (ASH), the Director,
Centers for Disease Control and
Prevention (CDC), and the Director,
Center for Preparedness and Response
(CPR), concerning strategies and goals
for the programs and research within
CPR, monitoring the overall strategic
direction and focus of the CPR Divisions
and Offices, and administration and
oversight of peer review for CPR
scientific programs. For additional
information about the Board, please
visit: https://www.cdc.gov/cpr/bsc/
index.htm.
Matters To Be Considered: The agenda
will include: (1) BSC CPR Polio
Containment Workgroup (PCWG)
Update; and (2) Strategic Capacity
Building and Innovation Program
Review Working Group Update. Agenda
items are subject to change as priorities
dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–03869 Filed 2–23–22; 8:45 am]
10367
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel;
(SEP)—RFA–TS–22–001: Identify and
Evaluate Potential Risk Factors for
Amyotrophic Lateral Sclerosis (ALS).
Date: June 17, 2022
Time: 8:30 a.m.–5:30 p.m., EDT.
Place: Videoconference.
Agenda: To review and evaluate grant
applications.
FOR FURTHER INFORMATION CONTACT:
Mikel Walters, Ph.D., Scientific Review
Officer, National Center for Injury
Prevention and Control, CDC, 4770
Buford Highway NE, Mailstop F–63,
Atlanta, Georgia 30341, Telephone
(404)639–0913, MWalters@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–03870 Filed 2–23–22; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10398 #57]
Medicaid and Children’s Health
Insurance Program (CHIP) Generic
Information Collection Activities:
Proposed Collection; Comment
Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
On May 28, 2010, the Office
of Management and Budget (OMB)
issued Paperwork Reduction Act (PRA)
guidance related to the ‘‘generic’’
clearance process. Generally, this is an
expedited process by which agencies
may obtain OMB’s approval of
SUMMARY:
E:\FR\FM\24FEN1.SGM
24FEN1
jspears on DSK121TN23PROD with NOTICES1
10368
Federal Register / Vol. 87, No. 37 / Thursday, February 24, 2022 / Notices
collection of information requests that
are ‘‘usually voluntary, low-burden, and
uncontroversial collections,’’ do not
raise any substantive or policy issues,
and do not require policy or
methodological review. The process
requires the submission of an
overarching plan that defines the scope
of the individual collections that would
fall under its umbrella. On October 23,
2011, OMB approved our initial request
to use the generic clearance process
under control number 0938–1148
(CMS–10398). It was last approved on
April 26, 2021, via the standard PRA
process which included the publication
of 60- and 30-day Federal Register
notices. The scope of the April 2021
umbrella accounts for Medicaid and
CHIP State plan amendments, waivers,
demonstrations, and reporting. This
Federal Register notice seeks public
comment on one or more of our
collection of information requests that
we believe are generic and fall within
the scope of the umbrella. Interested
persons are invited to submit comments
regarding our burden estimates or any
other aspect of this collection of
information, including: the necessity
and utility of the proposed information
collection for the proper performance of
the agency’s functions, the accuracy of
the estimated burden, ways to enhance
the quality, utility and clarity of the
information to be collected, and the use
of automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
DATES: Comments must be received by
March 10, 2022.
ADDRESSES: When commenting, please
reference the applicable form number
(see below) and the OMB control
number (0938–1148). To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: CMS–10398 (#74)/OMB
control number: 0938–1148, Room C4–
26–05, 7500 Security Boulevard,
Baltimore, Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
VerDate Sep<11>2014
16:46 Feb 23, 2022
Jkt 256001
proposed collection(s) summarized in
this notice, you may access CMS’
website at https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
FOR FURTHER INFORMATION CONTACT:
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION: Following
is a summary of the use and burden
associated with the subject information
collection(s). More detailed information
can be found in the collection’s
supporting statement and associated
materials (see ADDRESSES).
Generic Information Collection
1. Title of Information Collection:
Medicaid Section 1115 Substance Use
Disorder (SUD) Demonstration:
Monitoring Reports Documents and
Templates; Type of Information
Collection Request: Revision of a
currently approved collection; Use: On
November 1, 2017, CMS released a letter
#17–003 to all state Medicaid Directors
announcing new directions on how
CMS would like to work with states on
section 1115(a) demonstrations to
improve access to and quality of
treatment for Medicaid beneficiaries as
part of a Department-wide effort to
combat the ongoing opioid crisis. The
letter also announced that CMS is now
offering a more flexible, streamlined
approach to accelerate states’ ability to
respond to the national opioid crisis
while enhancing states’ monitoring and
reporting of the impact of any changes
implemented through these
demonstrations.
Medicaid Section 1115 demonstration
monitoring and evaluation Special
Terms and Conditions (STC), and the
letter #17–003, make clear that CMS
remains committed to ensuring state
accountability for the health and wellbeing of Medicaid enrollees and that
monitoring and evaluation are
important for understanding the
outcomes and impacts of approaches to
Medicaid SUD demonstrations. For this
purpose, CMS is undertaking efforts to
help states monitor the elements of
these demonstrations, while giving them
the flexibility to adapt to changing
conditions in their states. States with
approved SUD demonstrations are
required to develop implementation and
monitoring plans, including monitoring
metrics, a monitoring protocol, and
regular monitoring reports describing
their implementation progress.
In addition, the STCs for these section
1115 demonstrations address that states
are required to submit in their regular
monitoring reports, information on
milestones and performance measures
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
that they elected to represent key
indicators of progress toward meeting
the goals for the demonstrations.
Furthermore, to improve the quality
and efficiency of the reporting
requirements for SUD demonstrations,
CMS in conjunction with state advisory
groups developed a set of standardized
monitoring tools for states to use for
their regular reporting, including:
• The Medicaid section 1115 SUD
demonstration monitoring protocol
template (this is a one-time submission);
• The Medicaid section 1115 SUD
demonstration monitoring protocol
workbook (this is a one-time
submission);
• The Medicaid section 1115 SUD
demonstration monitoring report
template, and;
• The Medicaid Section 1115 SUD
demonstration monitoring report
workbook.
As specified in official 1115 policy
communications to states:
In accordance with 42 CFR 431.428
states must submit all post-approval
deliverables as stipulated by CMS and
within the timeframes outlined within
the STCs for the specific Medicaid 1115
State Demonstration.
The State Medicaid Director Letter,
#17–003, entitled, Strategies Addressing
the Opioid Epidemic, provides a
framework for SUD demonstrations
under Medicaid Section 1115 Authority.
This letter indicates that a state’s
application should confirm its
commitment to assuring the necessary
resources to support robust monitoring
protocol and evaluation, and that the
state will provide an implementation
plan subject to CMS approval. The letter
further states that information about the
specific measures and reporting will be
detailed in a monitoring protocol agreed
upon by CMS and the state after
approval of the demonstration which
will demonstrate progress toward
meeting the goals for this demonstration
initiative.
In addition, the STCs for the Medicaid
section 1115 SUD demonstrations
require that approved states submit an
SUD implementation plan subject to
CMS approval, and an SUD monitoring
protocol to be developed in cooperation
with CMS and which is subject to CMS
approval. The SUD monitoring protocol,
reporting templates, and associated
monitoring metrics flow down from the
OMB-approved SUD implementation
plan, which aligns with the goals and
objectives of the demonstration as
expressed in SMDL #17–003.
The STCs also require approved states
to submit three quarterly and one
annual monitoring reports consistent
with the elements provided in 42 CFR
E:\FR\FM\24FEN1.SGM
24FEN1
Federal Register / Vol. 87, No. 37 / Thursday, February 24, 2022 / Notices
jspears on DSK121TN23PROD with NOTICES1
431.428 and in accordance with a
framework to be provided by CMS. The
STCs also provide that the monitoring
framework be subject to change as
monitoring systems are developed and
evolve, and that states are required to
report in a structured manner that
supports federal tracking and analysis.
In this 2022 information collection
request, we have revised the following
monitoring tools:
• Monitoring protocol tools:
Æ Monitoring protocol workbook
(updated to Version 6.0)
Æ Monitoring protocol template
(updated to Version 4.0)
• Monitoring report tools:
Æ Monitoring report template
(updated to Version 4.0)
Æ Monitoring report workbook
(updated to Version 6.0)
This 2022 release incorporates
updated guidance on reporting metrics,
narrative information, and other
clarifications. This release also reflects
modifications to align with the
Medicaid Section 1115 Substance Use
Disorder Demonstrations: Technical
Specifications for Monitoring Metrics
Manual Version 4.0 (released September
2021).
In addition, this release incorporates
updated functionality in the
Performance Metrics Database &
Analytics (PMDA) system aimed to
automate aspects of reporting and
customize tools to ease state burden.
Updated functionality includes:
• Auto-population of certain fields
within the monitoring report tools in
alignment with the state’s CMSapproved monitoring protocol.
• Reporting flagged items early in the
process to reduce resubmission and
allow CMS to engage with the state
faster and on a more detailed level.
• Ensuring the latest version of the
monitoring tools are utilized by sending
an email notification to all designated
demonstration contacts when
customized monitoring report tools are
available.
Form Number: CMS–10398 (#57)
(OMB control number: 0938–1148);
Frequency: Once, yearly, and quarterly;
Affected Public: State, Local, or Tribal
Governments; Number of Respondents:
35; Total Annual Responses: 596; Total
Annual Hours: 6,394. For policy
questions regarding this collection
contact: Danielle Daly at 410–786–0897.
Dated: February 18, 2022.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2022–03936 Filed 2–23–22; 8:45 am]
BILLING CODE 4120–01–P
VerDate Sep<11>2014
16:46 Feb 23, 2022
Jkt 256001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0013]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Sanitary
Transportation of Human and Animal
Food
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency, or we) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on the information
collection requirements associated with
the sanitary transportation of human
and animal food.
DATES: Submit either electronic or
written comments on the collection of
information by April 25, 2022.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before April 25,
2022. The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of April 25, 2022. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
10369
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2013–N–0013 for ‘‘Agency Information
Collection Activities; Proposed
Collection; Comment Request; Sanitary
Transportation of Human and Animal
Food.’’ Received comments, those filed
in a timely manner (see ADDRESSES),
will be placed in the docket and, except
for those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
E:\FR\FM\24FEN1.SGM
24FEN1
Agencies
[Federal Register Volume 87, Number 37 (Thursday, February 24, 2022)]
[Notices]
[Pages 10367-10369]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03936]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifier: CMS-10398 #57]
Medicaid and Children's Health Insurance Program (CHIP) Generic
Information Collection Activities: Proposed Collection; Comment Request
AGENCY: Centers for Medicare & Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: On May 28, 2010, the Office of Management and Budget (OMB)
issued Paperwork Reduction Act (PRA) guidance related to the
``generic'' clearance process. Generally, this is an expedited process
by which agencies may obtain OMB's approval of
[[Page 10368]]
collection of information requests that are ``usually voluntary, low-
burden, and uncontroversial collections,'' do not raise any substantive
or policy issues, and do not require policy or methodological review.
The process requires the submission of an overarching plan that defines
the scope of the individual collections that would fall under its
umbrella. On October 23, 2011, OMB approved our initial request to use
the generic clearance process under control number 0938-1148 (CMS-
10398). It was last approved on April 26, 2021, via the standard PRA
process which included the publication of 60- and 30-day Federal
Register notices. The scope of the April 2021 umbrella accounts for
Medicaid and CHIP State plan amendments, waivers, demonstrations, and
reporting. This Federal Register notice seeks public comment on one or
more of our collection of information requests that we believe are
generic and fall within the scope of the umbrella. Interested persons
are invited to submit comments regarding our burden estimates or any
other aspect of this collection of information, including: the
necessity and utility of the proposed information collection for the
proper performance of the agency's functions, the accuracy of the
estimated burden, ways to enhance the quality, utility and clarity of
the information to be collected, and the use of automated collection
techniques or other forms of information technology to minimize the
information collection burden.
DATES: Comments must be received by March 10, 2022.
ADDRESSES: When commenting, please reference the applicable form number
(see below) and the OMB control number (0938-1148). To be assured
consideration, comments and recommendations must be submitted in any
one of the following ways:
1. Electronically. You may send your comments electronically to
https://www.regulations.gov. Follow the instructions for ``Comment or
Submission'' or ``More Search Options'' to find the information
collection document(s) that are accepting comments.
2. By regular mail. You may mail written comments to the following
address: CMS, Office of Strategic Operations and Regulatory Affairs,
Division of Regulations Development, Attention: CMS-10398 (#74)/OMB
control number: 0938-1148, Room C4-26-05, 7500 Security Boulevard,
Baltimore, Maryland 21244-1850.
To obtain copies of a supporting statement and any related forms
for the proposed collection(s) summarized in this notice, you may
access CMS' website at https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing.
FOR FURTHER INFORMATION CONTACT: William N. Parham at (410) 786-4669.
SUPPLEMENTARY INFORMATION: Following is a summary of the use and burden
associated with the subject information collection(s). More detailed
information can be found in the collection's supporting statement and
associated materials (see ADDRESSES).
Generic Information Collection
1. Title of Information Collection: Medicaid Section 1115 Substance
Use Disorder (SUD) Demonstration: Monitoring Reports Documents and
Templates; Type of Information Collection Request: Revision of a
currently approved collection; Use: On November 1, 2017, CMS released a
letter #17-003 to all state Medicaid Directors announcing new
directions on how CMS would like to work with states on section 1115(a)
demonstrations to improve access to and quality of treatment for
Medicaid beneficiaries as part of a Department-wide effort to combat
the ongoing opioid crisis. The letter also announced that CMS is now
offering a more flexible, streamlined approach to accelerate states'
ability to respond to the national opioid crisis while enhancing
states' monitoring and reporting of the impact of any changes
implemented through these demonstrations.
Medicaid Section 1115 demonstration monitoring and evaluation
Special Terms and Conditions (STC), and the letter #17-003, make clear
that CMS remains committed to ensuring state accountability for the
health and well-being of Medicaid enrollees and that monitoring and
evaluation are important for understanding the outcomes and impacts of
approaches to Medicaid SUD demonstrations. For this purpose, CMS is
undertaking efforts to help states monitor the elements of these
demonstrations, while giving them the flexibility to adapt to changing
conditions in their states. States with approved SUD demonstrations are
required to develop implementation and monitoring plans, including
monitoring metrics, a monitoring protocol, and regular monitoring
reports describing their implementation progress.
In addition, the STCs for these section 1115 demonstrations address
that states are required to submit in their regular monitoring reports,
information on milestones and performance measures that they elected to
represent key indicators of progress toward meeting the goals for the
demonstrations.
Furthermore, to improve the quality and efficiency of the reporting
requirements for SUD demonstrations, CMS in conjunction with state
advisory groups developed a set of standardized monitoring tools for
states to use for their regular reporting, including:
The Medicaid section 1115 SUD demonstration monitoring
protocol template (this is a one-time submission);
The Medicaid section 1115 SUD demonstration monitoring
protocol workbook (this is a one-time submission);
The Medicaid section 1115 SUD demonstration monitoring
report template, and;
The Medicaid Section 1115 SUD demonstration monitoring
report workbook.
As specified in official 1115 policy communications to states:
In accordance with 42 CFR 431.428 states must submit all post-
approval deliverables as stipulated by CMS and within the timeframes
outlined within the STCs for the specific Medicaid 1115 State
Demonstration.
The State Medicaid Director Letter, #17-003, entitled, Strategies
Addressing the Opioid Epidemic, provides a framework for SUD
demonstrations under Medicaid Section 1115 Authority. This letter
indicates that a state's application should confirm its commitment to
assuring the necessary resources to support robust monitoring protocol
and evaluation, and that the state will provide an implementation plan
subject to CMS approval. The letter further states that information
about the specific measures and reporting will be detailed in a
monitoring protocol agreed upon by CMS and the state after approval of
the demonstration which will demonstrate progress toward meeting the
goals for this demonstration initiative.
In addition, the STCs for the Medicaid section 1115 SUD
demonstrations require that approved states submit an SUD
implementation plan subject to CMS approval, and an SUD monitoring
protocol to be developed in cooperation with CMS and which is subject
to CMS approval. The SUD monitoring protocol, reporting templates, and
associated monitoring metrics flow down from the OMB-approved SUD
implementation plan, which aligns with the goals and objectives of the
demonstration as expressed in SMDL #17-003.
The STCs also require approved states to submit three quarterly and
one annual monitoring reports consistent with the elements provided in
42 CFR
[[Page 10369]]
431.428 and in accordance with a framework to be provided by CMS. The
STCs also provide that the monitoring framework be subject to change as
monitoring systems are developed and evolve, and that states are
required to report in a structured manner that supports federal
tracking and analysis.
In this 2022 information collection request, we have revised the
following monitoring tools:
Monitoring protocol tools:
[cir] Monitoring protocol workbook (updated to Version 6.0)
[cir] Monitoring protocol template (updated to Version 4.0)
Monitoring report tools:
[cir] Monitoring report template (updated to Version 4.0)
[cir] Monitoring report workbook (updated to Version 6.0)
This 2022 release incorporates updated guidance on reporting
metrics, narrative information, and other clarifications. This release
also reflects modifications to align with the Medicaid Section 1115
Substance Use Disorder Demonstrations: Technical Specifications for
Monitoring Metrics Manual Version 4.0 (released September 2021).
In addition, this release incorporates updated functionality in the
Performance Metrics Database & Analytics (PMDA) system aimed to
automate aspects of reporting and customize tools to ease state burden.
Updated functionality includes:
Auto-population of certain fields within the monitoring
report tools in alignment with the state's CMS-approved monitoring
protocol.
Reporting flagged items early in the process to reduce
resubmission and allow CMS to engage with the state faster and on a
more detailed level.
Ensuring the latest version of the monitoring tools are
utilized by sending an email notification to all designated
demonstration contacts when customized monitoring report tools are
available.
Form Number: CMS-10398 (#57) (OMB control number: 0938-1148);
Frequency: Once, yearly, and quarterly; Affected Public: State, Local,
or Tribal Governments; Number of Respondents: 35; Total Annual
Responses: 596; Total Annual Hours: 6,394. For policy questions
regarding this collection contact: Danielle Daly at 410-786-0897.
Dated: February 18, 2022.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office of Strategic Operations and
Regulatory Affairs.
[FR Doc. 2022-03936 Filed 2-23-22; 8:45 am]
BILLING CODE 4120-01-P